ABSTRACT
Background Vascular dementia (VaD) accounts for 15-20% of all dementia cases. It is a syndrome of acquired cognitive impairment with a complex pathophysiological basis. A novel herbal formulation (Sailuotong; SLT) consisting of Panax ginseng, Ginkgo biloba and Crocus sativus extracts was developed to treat VaD. Preclinical animal studies found significant improvements in memory and in pathogenic biochemical parameters. Appropriate safety of SLT was shown in acute and chronic toxicity studies, and early clinical trials of SLT demonstrated enhancements in cognition in VaD patients. A fully powered study with a long intervention period is needed to confirm the efficacy and safety of this novel intervention.
Methods A rigorous phase III clinical trial was developed with the aim of recruiting 238 patients diagnosed with mild to moderate probable VaD, or VaD mixed with Alzheimer’s disease (where cerebrovascular disease is the clinical dominant contributor to dementia, abbreviated as CVD+AD). Using a permuted block strategy, participants will be randomly allocated to receive SLT (120 mg bd) or placebo capsules for an intervention period of 52 weeks and will be followed-up for an additional 13 weeks. The primary outcome measures are the Vascular Dementia Assessment Scale-cognitive subscale and Alzheimer’s Disease Cooperative Study-Activities of Daily Living scale. Secondary outcome measures include the Clinician’s Interview Based Impression of Change-Plus, CLOX, EXIT-25, Neuropsychiatric Inventory-Clinician rating scale, and Dementia Quality of Life questionnaire. Safety is assessed through adverse event reports and liver, renal, and coagulation studies.
Discussion Primary and secondary outcome measures will be compared between treatment and placebo groups, using intention to treat and per protocol analyses. We hypothesise that a 52-week treatment of SLT will be clinically effective and well tolerated in participants with VaD or AD+CVD. This project will provide vital efficacy and safety data for this novel treatment approach to VaD.
Trial registration Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN 12616000057482. Registered on 20 January 2016. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369471&isReview=true
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ACTRN12616000057482
Funding Statement
Australia Shineway Technology Pty Ltd provide the funding and medication to support the conduct of this trial. The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of South West Sydney Local Health District and Western Sydney University gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.
ABBREVIATIONS
- VaD
- Vascular dementia
- AD
- Alzheimer’s Disease
- CVD
- Cerebrovascular Disease
- CVD+AD
- Cerebrovascular Disease mixed with Alzheimer’s Disease
- SLT
- Sailuotong
- NINDS-AIREN
- National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l’Enseignement en Neurosciences
- NINCDS-ADRDA
- National Institute of Neurological and Communication Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association
- HR
- Heart Rate
- BP
- Blood Pressure
- Ht
- Height
- Wt
- Weight
- MMSE
- Mini Mental State Exam
- GDS
- Geriatric Depression Scale
- VaDAS-cog
- Vascular Dementia Assessment Scale-cognitive subscale
- ADCS-ADL
- Alzheimer’s Disease Cooperative Study-Activities of Daily Living
- CIBIC-Plus
- Clinician’s Interview Based Impression of Change-Plus
- NPI-C
- Neuropsychiatric Inventory-Clinician scale
- DEMQOL
- Dementia Quality of Life questionnaire
- Con meds
- Concomitant medications
- AE
- Adverse Event
- SAE
- Serious Adverse Event
- ULN
- Upper Limit of Normal
- TGA
- Therapeutic Goods Administration
- PI
- Principal Investigator
- DSMB
- Data and Safety Monitoring Board
